North America Medical Foods for Inborn Errors of Metabolism Market, By Products (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula With Iron, Low-Calcium/Vitamin D-Free Infant Formula With Iron, Low Protein Food and Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I And II, Urea Cycle Disorders and Others), Forms (Powder, Liquids, Gels and Others) Packaging (Can, Jar, Packets, Bottle and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
North America Medical Foods for Inborn Errors of Metabolism Market Analysis and Size
In comparison to enzyme-based therapeutic medicines, consumption of nutraceutical supplements and prescribed medical food is increasing. The rising cost of healthcare, as well as consumers' preference for simple and effective disease management remedies, are likely to shift the lineage away from pharmaceuticals and toward medical supplements and nutritional foods. Medical food demand has increased over the previous year due to increased medical food expenditure and the introduction of novel products for new indications.
Data Bridge Market Research analyses that the medical foods for inborn errors of metabolism market value is USD 1035.45 million in 2022, is expected to reach USD 2752.70 million by 2030, at a CAGR of 13.00% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Medical Foods for Inborn Errors of Metabolism Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula With Iron, Low-Calcium/Vitamin D-Free Infant Formula With Iron, Low Protein Food and Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I And II, Urea Cycle Disorders and Others), Forms (Powder, Liquids, Gels and Others) Packaging (Can, Jar, Packets, Bottle and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America
|
|
Market Players Covered
|
Nestlé Health Science (Switzerland), Nutricia (Netherlands), Solace Nutrition (U.S.), Abbott (U.S.), Mead Johnson & Company, LLC. (U.S.), BioMarin Pharmaceutical (U.S.), Ajinomoto Cambrooke, Inc. (U.S.), Poa Pharma (Sweden), PKU-MDmil (U.S.), Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italy), Pristine Organics Pvt. Ltd. (India), APR (U.S.), Ener-G foods, INC (U.S.) and Promin Metabolics (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Inborn metabolic errors (IEMs) can be successfully treated to modern treatment. Medical foods are Medical foods are created for patients whose ability to consume, digest, absorb or metabolise typical meals or nutrients is limited or compromised, making it impossible to regulate their diets only by dietary changes to the typical diet.
North America Medical Foods for Inborn Errors of Metabolism Market Dynamics
Drivers
- Rising usage of New-born screening
New-born screening is a well-established medical procedure, a successful preventative public health initiative, and an essential health benefit. To achieve the benefits of neonatal screening, the use of medicinal foods is required. The success of PKU new born screening and the following dietary intervention using medical foods to treat the disease led to screening for other conditions that could be treated. As increased new born screening panels, there was an increase in the variety in conditions examined from state to state.
Opportunities
- Rising use of medical foods
The market is regulated by authoritative and regulatory food and diet supplement statuses, and medical foods are employed as therapy choices for inborn metabolic abnormalities. Between 85% and 90% of a person's dietary requirements are satisfied by the nutritional therapy for congenital metabolic abnormalities. These supplements are also almost completely side effect free making them safe for people of all ages. Private medical insurance in the US and a few other nations have recently started to provide reimbursement programmes for the use of specific medical meals. As a result, market expansion during the forecast period is anticipated to be driven by increased usage of medical food and nutrient supplements.
Restraints/Challenges
- Inadequate reimbursement scenario
An inadequate reimbursement scenario is expected to limit the use of medical food and slow the growth of the market during the forecast period.
- High cost of medical foods
Medical foods are created for people who have difficulty swallowing, digesting, absorbing or metabolising regular foods or nutrients and whose nutritional management cannot be accomplished solely by altering their regular diet. Many health insurance policies in the U.S. do not adequately cover medical foods and without insurance many families cannot afford their high cost.
This medical foods for inborn errors of metabolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medical foods for inborn errors of metabolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In 2019, In the Netherlands, Nutricia established a sustainable facility. The large investment in the Nutricia Cuijk facility raised the production of specialised infant formula and the market's income.
- In 2022, Mead Johnson & Company, LLC announced that it has merged entirely with Reckitt Benckiser Group plc (RB). It was anticipated that the Mead Johnson brand and business would continue to grow to the effective innovation and marketing practises used by Reckitt Benckiser plc businesses.
North America Medical Foods for Inborn Errors of Metabolism Market Scope
The medical foods for inborn errors of metabolism market is segmented on the basis of products, age group, diseases, forms, packaging and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Products
- Amino Acid
- Glytactin with GMP Amino Acid-Modified Infant Formula with Iron
- Low-Calcium/Vitamin D-Free Infant Formula with Iron
- Low Protein Food
- Others
Age Group
- Infants
- Weaning
- Adolescent
- Adults
Diseases
- Phenylketonuria (PKU)
- Maple Syrup Urine Disease (MSUD)
- Homocystinuria
- Methylmalonic Acidemia
- Organic Acidurias
- Propionic Acidemia
- Isovaleric Acidemia
- Disorders of Leucine Metabolism
- Glutaric Acidemia Type I Renal Disease
- Tyrosinemia Types I and II
- Urea Cycle Disorders
- Others
Forms
- Powder
- Liquids
- Gels and Others
Packaging
- Can
- Jar
- Packets
- Bottle
- Others
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Drugs Stores
- Online Pharmacies
- Others
Medical Foods for Inborn Errors of Metabolism Market Regional Analysis/Insights
The medical foods for inborn errors of metabolism market is analysed and market size insights and trends are provided by country, products, age group, diseases, forms, packaging and distribution channel as referenced above.
The countries covered in the medical foods for inborn errors of metabolism market report are U.S., Canada and Mexico in North America
U.S. is dominating in the market with increased awareness about the inborn errors of metabolism and their treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The medical foods for inborn errors of metabolism market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for medical foods for inborn errors of metabolism market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the medical foods for inborn errors of metabolism market. The data is available for historic period 2011-2021.
Competitive Landscape and Medical Foods for Inborn Errors of Metabolism Market Share Analysis
The medical foods for inborn errors of metabolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to medical foods for inborn errors of metabolism market.
Some of the major players operating in the medical foods for inborn errors of metabolism market are:
- Nestlé Health Science (Switzerland)
- Nutricia (Netherlands)
- Solace Nutrition (U.S.)
- Abbott (U.S.)
- Mead Johnson & Company, LLC. (U.S.)
- BioMarin Pharmaceutical (U.S.)
- Ajinomoto Cambrooke, Inc. (U.S.)
- Poa Pharma (Sweden)
- PKU-MDmil (U.S.)
- Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italy)
- Pristine Organics Pvt. Ltd.(India)
- APR (U.S.)
- Ener-G Foods (U.S.)
- Promin Metabolics (U.K.)
SKU-